In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Promega Corp.

www.promega.com

Latest From Promega Corp.

US Supreme Court Sides With Thermo Fisher In Diagnostics Patent Spat

The justices struck down an appeals court ruling that a single device component could count as a “substantial portion” under patent infringement laws.

Legal Issues Intellectual Property

US Urges High Court To Take Patent Case Claiming Overseas Inducement

The case between Promega and Life Tech turns on whether a company violates US patent law by shipping a single allegedly patented component overseas for assembly. The Solicitor General’s office says it does not, arguing that the Federal Circuit’s reading would expose US manufacturers to too much risk of patent liability.

Medical Device Legal Issues

Covalys Biosciences AG

Swiss start-up Covalys Biosciences AG believes it has developed a protein tag technology that will improve the way researchers label, immobilize and purify proteins. It's proprietary SNAP-tag, says the company, is more stale and versatile than existing protein tag technologies and can be employed anywhere proteins are studied.
BioPharmaceutical Europe

RNAi Revs Up

Scientists have recently recognized an apparently fundamental cellular mechanism that may be a sort of ancient immune system. Called RNAi, for RNA interference, the process utilizes pieces of double-stranded RNA to prevent gene expression. RNAi has quickly become a powerful research tool, but its real promise lies in its potential to generate a brand-new class of highly specific medicines. Researchers have only just begun to explore how RNAi works in mammalian cells, so there's no telling if it actually will give rise to therapeutics. A growing number of companies are betting they'll be able to turn the fad into fortunes. Already, some of the challenges to commercialization are obvious: how to deliver the RNA, and who if anyone will control intellectual property rights. Some firms aim to directly deliver short sequences of RNA, and those who travel this route may confront challenges similar to those faced by antisense companies. Others are trying gene therapy approaches and will inherit all the problems of that field. As in any new field, bluster and blather are mixed with secrecy about who has what in terms of technology, money, and patents. The winner is likely to be the first company that can reduce concept to practice, and come up with a drug that works.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ophidian Pharmaceuticals Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Promega Corp.
  • Senior Management
  • William A Linton, Pres. & CEO
    Dr. Randal Dimond, VP, Research
  • Contact Info
  • Promega Corp.
    Phone: (608) 274-4330
    2800 Woods Hollow Rd.
    Madison, WI 53711-5399
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register